tiprankstipranks
Advertisement
Advertisement
Cabaletta Bio presents new data for rese-cel in autoimmune diseases
PremiumThe FlyCabaletta Bio presents new data for rese-cel in autoimmune diseases
2M ago
Cabaletta Bio Highlights Rese-cel Data and Pivotal Path
Premium
Company Announcements
Cabaletta Bio Highlights Rese-cel Data and Pivotal Path
2M ago
Douglas Tsao Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target on Rese-cel’s Emerging Commercial Profile and Conditioning-Free Edge
Premium
Ratings
Douglas Tsao Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target on Rese-cel’s Emerging Commercial Profile and Conditioning-Free Edge
2M ago
Cabaletta Bio Reports Encouraging RESET-PV Trial Data
PremiumCompany AnnouncementsCabaletta Bio Reports Encouraging RESET-PV Trial Data
2M ago
Cabaletta Bio Maintained at Buy as Emerging Rese-cel Data Support Preconditioning-Free Potential; $13 Price Target Reaffirmed
Premium
Ratings
Cabaletta Bio Maintained at Buy as Emerging Rese-cel Data Support Preconditioning-Free Potential; $13 Price Target Reaffirmed
3M ago
Cabaletta Bio financing overhang concerns should be addressed, says Cantor
Premium
The Fly
Cabaletta Bio financing overhang concerns should be addressed, says Cantor
3M ago
Cabaletta Bio, Cellares enter 10-year commercial agreement
PremiumThe FlyCabaletta Bio, Cellares enter 10-year commercial agreement
3M ago
Cabaletta Bio: RESET-MG Data and Differentiated Autoimmune Strategy Underpin Buy Rating and Upside Potential
Premium
Ratings
Cabaletta Bio: RESET-MG Data and Differentiated Autoimmune Strategy Underpin Buy Rating and Upside Potential
3M ago
Cabaletta Bio Updates rese-cel Autoimmune Therapy Development Plans
Premium
Company Announcements
Cabaletta Bio Updates rese-cel Autoimmune Therapy Development Plans
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100